Apoptosis and Sjögren syndrome

Seminars in Arthritis and Rheumatism

Volumn 33, Issue 1, 2003, Pages 49-65

  Manganelli, Paolo ^a,b   Fietta, Pieranna ^a  

^a Parma Hospital   (Italy)

^b Parma Hospital   (Italy)

Author keywords

Apoptosis; Bax; Bcl 2; Bcl x; Caspases; CD4+ T cells; Fas FasL interaction; P21; P53; Sj gren syndrome

Indexed keywords

AUTOANTIBODY; CASPASE; FAS LIGAND; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P53;

APOPTOSIS; AUTOIMMUNE DISEASE; CELL DEATH; DNA STRAND BREAKAGE; EPITHELIUM CELL; HUMAN; HUMAN CELL; INFLAMMATORY CELL; JOINT DESTRUCTION; LYMPHOCYTOPENIA; MONONUCLEAR CELL; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SJOEGREN SYNDROME; TISSUE SECTION;

EID: 0041826773     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1053/sarh.2003.50019     Document Type: Article

References (89)

1. Kerr JF, Wyllie AH, Currie AR. Apoptosis, a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57.
2. Saikumar P, Dong Z, Mikhailov V, Denton M, Weinberg JM, Venkatachalam MA. Apoptosis: definition, mechanisms and relevance to disease. Am J Med 1999;107:489-506.
3. Cohen JJ. Apoptosis. Immunol Today 1993;14:126-30.
4. Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997;326:1-16.
5. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998;17:1675-87.
6. Scaffidi C, Schmitz I, Zha J, Korsmeyer SJ, Krammer PH, Peter ME. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J Biol Chem 1999;274:22532-8.
7. Granville DJ, Carthy CM, Hunt DWC, McManus BM. Apoptosis: molecular aspects of cell death and disease. Lab Invest 1998;78:893-913.
8. McConkey DJ, Orrenius S, Jondal M. Cellular signaling in programmed cell death (apoptosis). Immunol Today 1990;11:120-1.
9. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
10. Vaishnaw AK, McNally JD, Elkon KB. Apoptosis in the rheumatic diseases. Arthritis Rheum 1997;40:1917-27.
11. Moutsopoulos HM, Chused TM, Mann DL, Klippel JH, Fauci AS, Frank MM, et al. Sjögren's syndrome (sicca syndrome): current issues. Ann Intern Med 1980;92:212-26
12. Skopouli FN, Fox PC, Galanopoulou V, Atkinson JC, Jaffe ES, Moutsopoulos HM. T cell subpopulations in the labial minor salivary gland histopathologic lesion of Sjögren's syndrome. J Rheumatol 1991;18:210-4.
13. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002;20:323-70.
14. Patel YI, McHugh NJ. Apoptosis-new clues to the pathogenesis of Sjögren's syndrome? Rheumatology 2000;39: 119-21.
15. Kong L, Ogawa N, Nakabayashi T, Liu GT, D'Souza E, McGuff HS, et al. Fas and Fas ligand expression in the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum 1997;40:87-97.
16. Nakamura H, Kawakami A, Tominaga M, Migita K, Kawabe Y, Nakamuta T, et al. Expression of CD40/CD40 ligand and Bcl-2 family proteins in labial salivary glands of patients with Sjögren's syndrome. Lab Invest 1999;79:261-9.
17. Anaya J-M, McGuff HS, Banks PM, Talal N. Clinicopathological factors relating malignant lymphoma with Sjögren's syndrome. Semin Arthritis Rheum 1996;25:337-46.
18. Nakamura H, Kawakami A, Yamasaki S, Nakashima T, Kamachi M, Migita K, et al. Expression and function of X chromosome-linked inhibitor of apoptosis protein in Sjögren's syndrome. Lab Invest 2000;80:1421-7.
19. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997;388:300-4.
20. Sumida T, Matsumoto I, Murata H, Namekawa T, Matsumura R, Tomioka H, et al. TCR in Fas-sensitive T cells from labial salivary glands of patients with Sjögren's syndrome. J Immunol 1997;158:1020-5.
21. Matsumura R, Kagami M, Tomioka H, Tanabe E, Sugiyama T, Sueishi M, et al. Expression of ductal Fas antigen in sialoadenitis of Sjögren's syndrome. Clin Exp Rheumatol 1996; 14:309-11.
22. Matsumura R, Umemiya K, Kagami M, Tomioka H, Tanabe E, Sugiyama T, et al. Glandular and extraglandular expression of the Fas-Fas ligand and apoptosis in patients with Sjögren's syndrome Clin Exp Rheumatol 1998;16:561-8.
23. Kong L, Ogawa N, McGuff HS, Nakabayashi T, Sakata K, Masago R, et al. Bcl-2 family expression in salivary glands from patients With primary Sjögren's syndrome: involvement of Bax in salivary gland destruction. Clin Immunol Immunopathol 1998;88:133-41.
24. Nakamura H, Koji T, Tominaga M, Kawakami A, Migita K, Kawabe Y, et al. Apoptosis in labial salivary glands from Sjögren's syndrome (SS) patients: comparison with human T lymphotropic virus-I (HTLV-I)-seronegative and seropositive patients. Clin Exp Immunol 1998;114:106-12.
25. Polihronis M, Tapinos NI, Theocharis SE, Economou A, Kittas C, Moutsopoulos HM. Modes of epithelial cell death and repair in Sjögren's syndrome (SS). Clin Exp Immunol 1998; 114:485-90.
26. Playford RJ, Marchbank T, Goodlab RA, Chinery RA, Poulsom R, Hanby AM. Transgenic mice that overexpress the human trefoil peptide pS2 have an increased resistance to intestinal damage. Proc Natl Acad Sci USA 1996;93:2137-42.
27. Darmon AJ, Ley TJ, Nicholson DW, Bleackley RC. Cleavage of CPP32 by granzyme B represents a critical role for granzyme B in the induction of target cell DNA fragmentation. J Biol Chem 1996;271:2109-12.
28. Atkinson EA, Barry M, Darmon AJ, Shostak I, Turner PC, Moyer RW, et al. Cytotoxic T lymphocyte-assisted suicide. Caspase 3 activation is primarily the results of the direct action of granzyme B. J Biol Chem 1998;273:21261-6.
29. Dardick I, Byard RW, Carnegie JA. A review of the proliferative capacity of major salivary glands and the relationship to current concepts of neoplasia in salivary glands. Oral Surg Oral Med Oral Pathol 1990;69:53-67.
30. Shibata Y, Hishikawa Y, Izumi S, Fujita S, Yamaguchi A, Koji T. Involvement of Fas/Fas ligand in the induction of apoptosis in chronic sialadenitis of minor salivary glands including Sjögren's syndrome. Hum Cell 2002;15:52-60.
31. Masago R, Aiba-Masago S, Talal N, Zuluaga FJ, Al-Hashimi I, Moody M, et al. Elevated proapoptotic Bax and caspase 3 activation in the NOD.scid model of Sjögren's syndrome. Arthritis Rheum 2001;44:693-702.
32. Jimenez F, Aiba-Masago S, Al Hashimi I, Vela-Roch N, Fernandes G, Yeh C-K, et al. Activated caspase 3 and cleaved poly(ADP-ribose)polymerase in salivary epithelium suggest a pathogenetic mechanism for Sjögren's syndrome. Rheumatology 2002;41:338-42.
33. Mariette X, Sibilia J, Roux S, Meignin V, Janin A. A new defensive mechanism to prevent apoptosis in salivary ductal cells from patients with Sjögren's syndrome: over-expression of p53 and p21. Rheumatology 2002;41:96-9.
34. Shen Y, White E. p53-dependent apoptotic pathways. Adv Cancer Res 2001;82:55-84.
35. Manganelli P, Quaini F, Andreoli AM, Lagrasta C, Pilato FP, Zuccarelli A, et al. Quantitative analysis of apoptosis and bcl-2 in Sjögren's syndrome. J Rheumatol 1997;24:1552-7.
36. Ohlsson M, Skarstein K, Bolstad AI, Johannessen AC, Jonsson R. Fas-induced apoptosis is a rare event in Sjögren's syndrome. Lab Invest 2001;81:95-105.
37. Rischmueller M, Scott J, Beroukas D, Gannot G, Fletcher D, Gordon TP, et al. Salivary gland apoptosis in primary Sjögren's syndrome: a controlled study. Arthritis Rheum 1998;41:S325.
38. + T cells around acinar epithelial cells with apoptosis in patients with Sjögren's syndrome. J Immunol 1999;163:2226-35.
39. Zhang C, Ao Z, Seth A, Schlossman SF. A mitochondrial membrane protein defined by a novel monoclonal antibody is preferentially detected in apoptotic cells. J Immunol 1996;157:3980-7.
40. Koester SK, Roth P, Mikulka WR, Schlossman SF, Zhang C, Bolton WE. Monitoring early cellular responses in apoptosis is aided by the mitochondrial membrane-protein specific monoclonal antibody APO2.7. Cytometry 1997;29:306-12.
41. + and its ligand E-cadherin in salivary glands of patients with Sjögren's syndrome. Scand J Immunol 1998;27: 215-8.
42. Tsubota K, Fujita H, Tadano K, Onoda N, Tzuzaka K, Tajikeuchi T. Abnormal expression and function of Fas ligand of lachrymal glands and peripheral blood in Sjögren's syndrome with enlarged exocrine glands. Clin Exp Immunol 2002; 129:177-82.
43. Tsubota K, Fujita H, Tsuzaka K, Takeuchi T. Mikulicz's disease and Sjögren's syndrome. Invest Ophthalmol Vis Sci 2000;41:1666-73.
44. Tu WH, Shearn MA, Lee JC, Hopper J Jr. Interstitial nephritis in Sjögren's syndrome. Ann Intern Med 1968;69: 1163-70.
45. Adamson TC, Fox RI, Frisman DM, Howell FV. Immunohistologic analysis of lymphoid infiltrates in primary Sjögren's syndrome using monoclonal antibodies. J Immunol 1983;130:203-8.
46. Murata H, Kita Y, Sakamoto A, Matsumoto I, Matsumura R, Sugiyama T, et al. Limited TCR repertoire of infiltrating T cells in the kidneys of Sjögren's syndrome patients with interstitial nephritis. J Immunol 1995;155:4084-9.
47. Ichikawa Y, Arimori K, Yoshida M, Horiki, Hoshina Y, Morita K, et al. Abnormal expression of apoptosis-related antigens, Fas and bcl-2, on circulating T-lymphocyte subsets in primary Sjögren's syndrome. Clin Exp Rheumatol 1995;13: 307-13.
48. + T-lymphocytopenia without HIV infection: increased prevalence among patients with primary Sjögren's syndrome. Clin Exp Rheumatol 1995;13:609-16.
49. + lymphocytes in Sjögren's syndrome. Clin Exp Rheumatol 1996;14:125-30.
50. + T cells with lymphocyte activation and activity of disease in patients with primary Sjögren's syndrome. Arthritis Rheum 1999;42:1673-81.
51. Ogawa N, Dang H, Kong L, Anaya J-M, Liu GT, Talal N. Lymphocyte apoptosis and apoptosis-associated gene expression in Sjögren's syndrome. Arthritis Rheum 1996;39: 1875-85.
52. Ohashi H, Ogawa N, Goto Y, Karahashi T, Akamine N. Elevated Fas (CD95) and bcl-2 protein expression on T cells from patients with primary Sjögren's syndrome. Arthritis Rheum 1996;39:S288.
53. Tsunoda S, Kawano M, Koni I, Kasahara Y, Yachie A, Miyawaki T, et al. Diminished expression of CD59 on activated CD8+ T cells undergoing apoptosis in systemic lupus erythematosus and Sjögren's syndrome. Scand J Immunol 2000;51: 293-9.
54. Liu X-B, Masago R, Kong L, Zhang B-X, Masago S, Vela-Roch N, et al. G-protein signalling abnormalities mediated by CD95 in salivary epithelial cells. Cell Death Differ 2000;7:1119-26.
55. Ambudkar IS, Hiramatsu Y, Lockwich T, Baum BJ. Activation and regulation of calcium entry in rat parotid gland acinar cells. Crit Rev Oral Biol Med 1993;4:421-5.
56. Gannot G, Bermudez D, Lillibridge D, Fox PC. Fas and Fas-mediated effects on a human salivary cell line in vitro: a model for immune-mediated exocrine damage in Sjögren's syndrome. Cell Death Differ 1998;5:743-50.
57. Aiba-Masago S, Masago R, Talal N, Dang H. TGF-β1 upregulates Fas-mediated apoptosis on salivary gland acinar cells. Arthritis Rheum 1999;42:S193.
58. Matsumura R, Umemiya K, Goto T, Nakazawa T, Ochiai K, Kagami M, et al. Interferon gamma and tumor necrosis factor alpha induce Fas expression and anti-Fas mediated apoptosis in a salivary ductal cell line. Clin Exp Rheumatol 2000;18:311-8.
59. Kamachi M, Kawakami A, Yamasaki S, Hida A, Nakashima T, Nakamura H, et al. Regulation of apoptotic cell death by cytokines in a human salivary gland cell line: Distinct and synergistic mechanisms in apoptosis induced by tumor necrosis factor a and interferon γ. J Lab Clin Med 2002;139: 13-9.
60. McArthur C, Wang Y, Veno P, Zhang J, Fiorella R. Intracellular trafficking and surface expression of SS-A (Ro), SS-B (La), poly(ADP-ribose) polymerase and α-fodrin autoantigens during apoptosis in human salivary, gland cells induced by tumor necrosis factor-α. Arch Oral Biol 2002;47:443-8.
61. Abu-Helu R, Dimitriou ID, Kapsogeorgou EK, Moutsopoulos HM, Manoissakis MN. Induction of salivary gland epithelial cell injury in Sjögren's syndrome: in vitro assessment of T cell-derived cytokines and Fas protein expression. J Autoimmunity 2001;17:141-53.
62. Ishimaru N, Saegusa K, Yanagi K, Haneji N, Saito I, Hayashi Y. Estrogen deficiency accelerates autoimmune exocrinopathy in murine Sjögren's syndrome through Fas-mediated apoptosis. Am J Pathol 1999;155:173-81.
63. Saegusa K, Ishimaru N, Yanagi K, Mishima K, Arakahi R, Suda T, et al. Prevention and induction of autoimmune exocrinopathy is dependent on pathogenic autoantigen cleavage in murine Sjögren's syndrome. J Immunol 2002;169:1050-7.
64. De Saint Jean M, Brignole F, Feldmann G, Goguel A, Baudouin C. Interferon-γ induces apoptosis and expression of inflammation-related proteins in Chang conjunctival cells. Invest Ophthalmol Vis Sci 1999;40:2199-22.
65. Skarstein K, Nerland AH, Eidsheim M, Mountz JD, Jonsson R. Lymphoid cell accumulation in salivary glands of autoimmune MRL mice can be due to impaired apoptosis. Scand J Immunol 1997;46:373-8.
66. Jabs D, Lee B, Whittum-Hudson J, Prendergast RA. The role of Fas-Fas ligand-mediated apoptosis in autoimmune lacrimal gland disease in MRL/MpJ mice. Invest Ophthalmol Vis Sci 2001;42:399-401.
67. Toda I, Rocha EM, Silveira LA, Wickham LA, Sullivan DA. Gender-related difference in the extent of lymphocytic infiltration in lacrimal and salivary glands of mouse models of Sjögren's syndrome. Invest Ophthalmol Vis Sci 1997;Suppl 34, S434.
68. Toda I, Wickham LA, Sullivan DA. Gender and androgen treatment influence the expression of proto-oncogenes and apoptotic factors in lacrimal and salivary tissues of MRL/Ipr mice. Clin Immunol Immunopathol 1998;86:59-71.
69. Toda I, Sullivan BD, Wichkam LA, Sullivan DA. Gender-and androgen-related influence on the expression of protooncogene and apoptotic factor mRNAS in lacrimal glands of autoimmune and non-autoimmune mice. J Steroid Biochem Mol Biol 1999;71:49-61.
70. Fleck M, Kern ER, Zhou T, Lang B, Mountz JD. Murine cytomegalovirus induces a Sjögren's-like disease in C57B1/7-lpr/lpr mice. Arthritis Rheum 1998;41:2175-84.
71. Fleck M, Zhang H-G, Kern ER, Hsu H-C, Müller-Ladner U, Mountz JD. Treatment of chronic sialadenitis in a murine model of Sjögren's syndrome by local fasL gene transfer. Arthritis Rheum 2001;44:964-73.
72. Kong L, Robinson CP, Peck AB, Vela-Roch N, Sakata K-M, Dang H, et al. Inappropriate apoptosis of salivary and lacrimal gland epithelium of immunodeficient NOD-scid mice. Clin Exp Rheumatol 1998;16:675-81.
73. Masao R, Aiba-Masago S, Talal N, Zuluaga FJ, Al-Hashimi I, Moody M, et al. Elevated proapoptotic Bax and caspase 3 activation in the NOD.scid model of Sjögren's syndrome. Arthritis Rheum 2001;44:693-702.
74. Robinson CP, Cornelius J, Bounous DE, Yamamoto H, Humphreys-Beher MG, Peck AB. Characterization of the changing lymphocyte populations and cytokine expression in the exocrine tissues of autoimmune NOD mice. Autoimmunity 1998;27:29-44.
75. Saito I, Haruta K, Shimuta M, Inoue H, Sakurai H, Yamada K, et al. Fas ligand-mediated exocrinopathy resembling Sjögren's syndrome in mice transgenic for IL-10. J Immunol 1999;162:2488-94.
76. Haneji N, Hamano H, Yanagi K, Hayashi Y. A new animal model for primary Sjögren's syndrome in NFS/sld mutant mice. J Immunol 1994;153:2769-77.
77. Hayashi Y, Yayagi K, Haneji N. Involvement of apoptotic protease cascade for tissue destruction in Sjögren's syndrome. Arch Immunol Ther Exp 2000;48:399-403.
78. Ishimaru N, Yoneda T, Saegusa K, Yanagi K, Haneji N, Moriyama K, et al. Severe destructive autoimmune lesions with aging in murine Sjögren's syndrome through Fas-mediated apoptosis. Am J Pathol 2000;156:1557-64.
79. th Edition, Volume 2, Chapter 85;Koopman WJ Ed; Lippincott Williams § Wilkins 2000;1736-59.
80. Price EJ, Vanables JW. The etiopathogenesis of Sjögren's syndrome. Semin Arthritis Rheum 1995;25:117-33.
81. Parke AL. Sjögren's syndrome: a women's health problem. J Rheumatol 2000;27 (Suppl 61):4-5.
82. Gao J, Schwalb TA, Addeo JV, Ghoson CR, Stern ME. The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: the effect of topical Cyclosporin A therapy. Cornea 1998;17:654-63.
83. Tsubota K, Fujita H, Tadano K, Takeuchi T, Murakami T, Saito I, et al. Improvement of lacrimal function by topical application of CyA in murine models of Sjögren's syndrome. Invest Ophthalmol Vis Sci 2001;42:101-110.
84. Anaya J-M, Talal N. Sjögren's syndrome comes of age. Semin Arthritis Rheum 1999;28:355-9.
85. Humphreys-Beher MG, Peck AB, Dang H, Talal N. The role of apoptosis in the initiation of the autoimmune response in Sjögren's syndrome. Clin Exp Immunol 1999;116:383-7.
86. Tapinos NI, Polihronis M, Tzioufas AG, Moutsopoulos HM. Sjögren's syndrome. Autoimmune epithelitis. Adv Exp Med Biol 1999;455:127-34.
87. Vallinoto C, Brucato A, Sabbadini MG, Bondanza A, Zimmermann V, Rugarli C, et al. Requirements for anti-Ro/ anti-La antibodies binding to apoptotic cells: Dendritic cell recruitment and possible involvement in the pathogenesis of SS. VII International Symposium on Sjögren's syndrome. Clin Exp Rheumatol 2000;18:124 (I0-23 Abstract).
88. Pérez P, Goicovich E, Alliende C, Aguilera S, Leyton C, Molina C, et al. Differential expression of matrix metalloproteinases in labial salivary glands of patients with primary Sjögren's syndrome. Mechanisms of exocrine parenchyma destruction. Arthritis Rheum 2000;43:2807-11.
89. Salk K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CSA Phase 3 Study Group. Ophthalmology 2000;107:631-9.